History of Letters to the Editor
Neurology Minute
As we celebrate the 75th anniversary of Neurology®, Drs. Jeff Ratliff, Steven Galetta, and Robert Griggs discuss the history and evolution of the Letters to the Editor section. Join the conversation by visiting the .
info_outline
Landmark Clinical Trials Shaping Patient Care
Neurology Minute
Dr. H.E. Hinson and Dr. Vijay Ramanan discuss the upcoming Clinical Trials Plenary Session at the AAN Annual Meeting and the landmark studies shaping neurological care. For more information about this event, .
info_outline
TRPM8 Antagonism with Elismetrep: A Novel Approach for Treating Migraine - Part 1
Neurology Minute
In part one of this series, Dr. Tesha Monteith and Dr. Brett Lauring discuss the potential role TRPM8 antagonist may play in the management of migraine. Read more about this abstract on the .
info_outline
FDA Revises Trial Requirements for Drug and Medical Product Approval - Part 2
Neurology Minute
In part two of this series, Dr. Justin Abbatemarco and Lizzy Lawrence discuss recent FDA guidance, focusing on broader agency changes and how this messaging differs from the FDA’s traditional communication around regulatory decision-making. Show citation:
info_outline
April 2026 President Spotlight: Supporting Neurology in Every Practice Setting
Neurology Minute
In the March episode of the President's Spotlight, Dr. Jason Crowell and Dr. Natalia Rost discuss some of the most pressing challenges facing academic neurology while supporting neurologists in all practice settings. Stay informed by watching the video.
info_outline
Antiseizure Medication Dosing Strategy During Pregnancy and Early Postpartum in Women With Epilepsy in MONEAD
Neurology Minute
Dr. Derek Stitt and Dr. Page B. Pennell discuss antiseizure medication management during pregnancy and postpartum, based on the MONEAD study. Show citation: Pennell PB, Li D, Kerr WT, et al. Antiseizure Medication Dosing Strategy During Pregnancy and Early Postpartum in Women With Epilepsy in MONEAD. Neurology. 2026;106(2):e214483. doi:
info_outline
FDA Revises Trial Requirements for Drug and Medical Product Approval - Part 1
Neurology Minute
In part one of this series, Dr. Justin Abbatemarco and Lizzy Lawrence discuss the FDA’s shift toward single-trial drug approvals. Show citation:
info_outline
Real-World Implementation of an AI Clinical Assistant in Neurology
Neurology Minute
Dr. Halley Alexander and Dr. Mikael Guzman Karlsson discuss the development and evaluation of an AI-enabled clinical assistant designed to support time-sensitive decision-making in neurology. View the related abstract:
info_outline
A Roadmap to Neurological Health Equity - Part 2
Neurology Minute
In part two of this series, Dr. Tesha Monteith and Dr. Nimish A. Mohile discuss the motivation behind the development of this roadmap to neurological health equity. Show citation: Patel PB, Hamilton RH, Budhu JA, et al. A Roadmap to Neurologic Health Equity: An AAN Position Statement. Neurology. 2026;106(5):e214687. doi:
info_outline
A Roadmap to Neurological Health Equity - Part 1
Neurology Minute
In the first part of this series, Dr. Tesha Monteith and Dr. Nimish A. Mohile discuss what the roadmap is and how it is intended to benefit practicing neurologists. Show citation: Patel PB, Hamilton RH, Budhu JA, et al. A Roadmap to Neurologic Health Equity: An AAN Position Statement. Neurology. 2026;106(5):e214687. doi:
info_outlineDr. Tesha Monteith and Dr. Patricia Pozo-Rosich discuss the latest advancements in headache medicine, focusing on key research findings from 2025.
Show transcript:
Dr. Tesha Monteith:
Hi, this is Tesha Monteith with the Neurology Minute. Welcome to our 2026 Headache Medicine Series. I've just been speaking with Patricia Pozo-Rosich about all of the exciting advances in headache medicine in 2025. For a minute, why don't you summarize some of the key advances in headache medicine research?
Dr. Patricia Pozo-Rosich:
I think that we have good news in headache. We are currently phase two trials for two or three different compounds, anti-part two, packup and new toxins. So we are actually, I think, excited to find out the phase 2B trial results and phase three. So well, that's something that I think is worth mentioning. Then I think it is important to remember that we have new data coming from real world evidence with long-term use of anti CGRP therapies. We also have data that shows that anti CGRP therapies are useful for patients with migraine and major depressive disorder, as well as as children. Finally, I think that it is very important to remind everyone that there are new papers on practice recommendations around the world on how we have to treat our patients with migraine, and that is related both to the acute and preventive therapies. And finally, couple of position statements that have been written by the International Hague Society that strive to improve the quality of how migraine individuals are treated, and that really conveys a paradigm shift where we probably should be starting preventive therapy sooner than later.
Dr. Tesha Monteith:
Great. Thank you so much for that quick summary. And please check out the Full Headache Medicine series. I appreciate talking to you, Patricia, and look forward to discussing more highlights next time.
Dr. Patricia Pozo-Rosich:
Thank you, Tisha. See you very soon.
Dr. Tesha Monteith:
And thank you for listening to the Neurology Minutes.